Getting Worse Not Better: UK Report On Access To Cancer Drugs
Executive Summary
A UK report on patient access to cancer drugs suggests that the European Medicines Agency could learn from the US Food and Drug Administration and best practice elsewhere in the world when it comes to taking a faster, more flexible approach to assessing evidence.
You may also be interested in...
Revamped Cancer Drugs Fund Means More Positive Recommendations, Says NICE
NICE, the health technology appraisal body for England and Wales, has rejected criticism that access to cancer drugs is worsening in the UK. The institute pointed to the revamped Cancer Drugs Fund which it said meant more positive recommendations.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.